Sun Pharma Launches Semaglutide Injection Under Brand Names Noveltreat, Sematrinity in India

Sun Pharmaceutical Industries Limited has announced the launch of its semaglutide injection under the brand names Noveltreat and Sematrinity in India. Noveltreat is indicated for chronic weight management in adults and is available in five dose strengths. Sematrinity is indicated for treatment of adults with insufficiently controlled type 2 diabetes mellitus and is available in two dose strengths. The weekly therapy costs for both drugs are significantly lower than the innovator brand, making them more affordable. The prefilled pens for both drugs are developed by leading global pharmaceutical device suppliers and manufactured in Europe.